Pirbright partners with animal health companies to develop PRRS vaccines

The Pirbright Institute has partnered with ECO Animal Health and The Vaccine Group to develop innovative PRRS vaccines.
calendar icon 16 October 2020
clock icon 4 minute read

The second ECO funded project will see Pirbright develop a significantly improved killed vaccine over 18 months. The team will generate modified PRRSV strains and then inactivate them to create vaccine candidates. The strain modifications aim to prevent inappropriate antibody responses and enhance those that are thought to provide immunity against multiple strains of PRRSV.

This killed vaccine would offer an attractive alternative to the current generation of live vaccines, which are only partially effective against different strains and suffer from safety constraints owing to the potential for the live vaccine virus to revert back to an infectious form.

Professor Simon Graham said: “Creating a killed vaccine that can prevent the spread of multiple strains would provide flexibility in tackling outbreaks as well as an improved safety profile, both vital for effective control.”

Dr Hafid Benchaoui, Head, Global R&D, ECO Animal Health Group said: This novel concept will provide better protection of pigs against PRRSV than current vaccines and will be safer by eliminating the significant risk of recombination in the field.”

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.